Emergent BioSolutions Inc.
EBS · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1 | $1 | $1 | $2 |
| % Growth | -0.5% | -6.1% | -37% | – |
| Cost of Goods Sold | $1 | $1 | $1 | $1 |
| Gross Profit | $0 | $0 | $0 | $1 |
| % Margin | 36% | 34.3% | 42.3% | 44.7% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $1 | $0 | -$0 |
| Operating Expenses | $0 | $1 | $1 | $0 |
| Operating Income | -$0 | -$1 | -$0 | $0 |
| % Margin | -10.4% | -69.2% | -15.2% | 19.2% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$0 | -$1 | -$0 | $0 |
| Tax Expense | $0 | $0 | -$0 | $0 |
| Net Income | -$0 | -$1 | -$0 | $0 |
| % Margin | -18.3% | -72.5% | -18.9% | 12.4% |
| EPS | -3.6 | -14.85 | -4.47 | 4.1 |
| % Growth | 75.8% | -232.2% | -209% | – |
| EPS Diluted | -3.6 | -14.85 | -4.47 | 4.06 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $0 | -$0 | $0 | $1 |
| % Margin | 5.1% | -4.5% | 1.4% | 28.4% |